Interlaboratory agreement in the monitoring of unfractionated heparin using the anti-factor Xa-correlated activated partial thromboplastin time
dc.contributor.author | Cuker, A. | en_US |
dc.contributor.author | Ptashkin, B. | en_US |
dc.contributor.author | Konkle, B. A. | en_US |
dc.contributor.author | Pipe, Steven W. | en_US |
dc.contributor.author | Whinna, H. C. | en_US |
dc.contributor.author | Zheng, X. L. | en_US |
dc.contributor.author | Cines, D. B. | en_US |
dc.contributor.author | Pollak, E. S. | en_US |
dc.date.accessioned | 2010-06-01T21:31:44Z | |
dc.date.available | 2010-06-01T21:31:44Z | |
dc.date.issued | 2009-01 | en_US |
dc.identifier.citation | CUKER, A.; PTASHKIN, B.; KONKLE, B. A.; PIPE, S. W.; WHINNA, H. C.; ZHENG, X. L.; CINES, D. B.; POLLAK, E. S. (2009). "Interlaboratory agreement in the monitoring of unfractionated heparin using the anti-factor Xa-correlated activated partial thromboplastin time." Journal of Thrombosis and Haemostasis 7(1): 80-86. <http://hdl.handle.net/2027.42/74583> | en_US |
dc.identifier.issn | 1538-7933 | en_US |
dc.identifier.issn | 1538-7836 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/74583 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=19017257&dopt=citation | en_US |
dc.format.extent | 264178 bytes | |
dc.format.extent | 3109 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.publisher | Blackwell Publishing Ltd | en_US |
dc.rights | © 2009 International Society on Thrombosis and Haemostasis | en_US |
dc.subject.other | Activated Partial Thromboplastin Time | en_US |
dc.subject.other | Anti-factor Xa | en_US |
dc.subject.other | Factor Xa Inhibition Assay | en_US |
dc.subject.other | Unfractionated Heparin | en_US |
dc.title | Interlaboratory agreement in the monitoring of unfractionated heparin using the anti-factor Xa-correlated activated partial thromboplastin time | en_US |
dc.type | Article | en_US |
dc.subject.hlbsecondlevel | Internal Medicine and Specialties | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | † Departments of Pediatrics and Pathology, University of Michigan, Ann Arbor, MI | en_US |
dc.contributor.affiliationother | * Department of Medicine and | en_US |
dc.contributor.affiliationother | † Departments of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA | en_US |
dc.contributor.affiliationother | § Department of Pathology, University of North Carolina, Chapel Hill, NC | en_US |
dc.contributor.affiliationother | ¶ Department of Pathology, Children’s Hospital of Philadelphia, Philadelphia, PA, USA | en_US |
dc.identifier.pmid | 19017257 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/74583/1/j.1538-7836.2008.03224.x.pdf | |
dc.identifier.doi | 10.1111/j.1538-7836.2008.03224.x | en_US |
dc.identifier.source | Journal of Thrombosis and Haemostasis | en_US |
dc.identifier.citedreference | Chiu HM, Hirsh J, Yung WL, Regoeczi E, Gent M. Relationship between the anticoagulant and antithrombotic effects of heparin in experimental venous thrombosis. Blood 1977; 49: 171 – 84. | en_US |
dc.identifier.citedreference | Basu D, Gallus A, Hirsh J, Cade J. A prospective study of the value of monitoring heparin treatment with the activated partial thromboplastin time. N Engl J Med 1972; 287: 324 – 7. | en_US |
dc.identifier.citedreference | Shapiro GA, Huntzinger SW, Wilson JE. Variation among commercial activated partial thromboplastin time reagents in response to heparin. Am J Clin Pathol 1977; 67: 477 – 80. | en_US |
dc.identifier.citedreference | Kitchen S, Jennings I, Woods TA, Preston FE. Wide variability in the sensitivity of APTT reagents for monitoring of heparin dosage. J Clin Pathol 1996; 49: 10 – 14. | en_US |
dc.identifier.citedreference | D’Angelo A, Seveso MP, D’Angelo SV, Gilardoni F, Dettori AG, Bonini P. Effect of clot-detection methods and reagents on activated partial thromboplastin time (APTT). Implications in heparin monitoring by APTT. Am J Clin Pathol 1990; 94: 297 – 306. | en_US |
dc.identifier.citedreference | Kitchen S, Preston FE. The therapeutic range for heparin therapy: relationship between six activated partial thromboplastin time reagents and two heparin assays. Thromb Haemost 1996; 75: 734 – 9. | en_US |
dc.identifier.citedreference | Bates SM, Weitz JI, Johnston M, Hirsh J, Ginsberg JS. Use of a fixed activated partial thromboplastin time ratio to establish a therapeutic range for unfractionated heparin. Arch Intern Med 2001; 161: 385 – 91. | en_US |
dc.identifier.citedreference | Brill-Edwards P, Ginsberg JS, Johnston M, Hirsh J. Establishing a therapeutic range for heparin therapy. Ann Intern Med 1993; 119: 104 – 9. | en_US |
dc.identifier.citedreference | Olson JD, Arkin CF, Brandt JT, Cunningham MT, Giles A, Koepke JA, Witte DL. College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy: laboratory monitoring of unfractionated heparin therapy. Arch Pathol Lab Med 1998; 122: 782 – 98. | en_US |
dc.identifier.citedreference | Hirsh J, Bauer KA, Donati MB, Gould M, Samama MM, Weitz JI. Parenteral anticoagulants: American College of Chest Physicians Evidence-based clinical practice guidelines (8th edition). Chest 2008; 133: 141S – 59S. | en_US |
dc.identifier.citedreference | Toulon P, Boutiere B, Horellou MH, Trzeciak MC, Samama MM. Monitoring heparin therapy using activated partial thromboplastin time – results of a multicenter trial establishing the therapeutic range for SILIMAT, a reagent with high sensitivity to heparin. Thromb Haemost 1998; 80: 104 – 8. | en_US |
dc.identifier.citedreference | Smythe MA, Koerber JM, Westley SJ, Nowak SN, Begle RL, Balasubramamiam M, Mattson JC. Use of the activated partial thromboplastin time for heparin monitoring. Am J Clin Pathol 2001; 115: 148 – 55. | en_US |
dc.identifier.citedreference | Baker BA, Adelman MD, Smith PA, Osborn JC. Inability of the activated partial thromboplastin time to predict heparin levels. Time to reassess guidelines for heparin assays. Arch Intern Med 1997; 157: 2475 – 9. | en_US |
dc.identifier.citedreference | Kitchen S, Theaker J, Preston FE. Monitoring unfractionated heparin therapy: relationship between eight anti-Xa assays and a protamine titration assay. Blood Coagul Fibrinolysis 2000; 11: 137 – 44. | en_US |
dc.identifier.citedreference | Kovacs MJ, Keeney M, MacKinnon K, Boyle E. Three different chromogenic methods do not give equivalent anti-Xa levels for patients on therapeutic low molecular weight heparin (dalteparin) or unfractionated heparin. Clin Lab Haematol 1999; 21: 55 – 60. | en_US |
dc.identifier.citedreference | Ignjatovic V, Summerhayes R, Gan A, Than J, Chan A, Cochrane A, Bennett M, Horton S, Shann F, Lane G, Ross-Smith M, Monagle P. Monitoring unfractionated heparin (UFH) therapy: which anti-factor Xa assay is appropriate? Thromb Res 2007; 120: 347 – 51. | en_US |
dc.identifier.citedreference | van den Besselaar AM, Meeuwisse-Braun J, Jansen-Gruter R, Bertina RM. Monitoring heparin therapy by the activated partial thromboplastin time – the effect of pre-analytical conditions. Thromb Haemost 1987; 57: 226 – 31. | en_US |
dc.identifier.citedreference | Adcock D, Kressin D, Marlar RA. The effect of time and temperature variables on routine coagulation tests. Blood Coagul Fibrinolysis 1998; 9: 463 – 70. | en_US |
dc.identifier.citedreference | Levine MN, Hirsh J, Gent M, Turpie AG, Cruickshank M, Weitz J, Anderson D, Johnson M. A randomized trial comparing activated thromboplastin time with heparin assay in patients with acute venous thromboembolism requiring large daily doses of heparin. Arch Intern Med 1994; 154: 49 – 56. | en_US |
dc.identifier.citedreference | Crafoord C. Preliminary report on post-operative treatment with heparin as a preventive of thrombosis. Acta Chir Scand 1937; 79: 407 – 26. | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.